Form 8-K - Current report:
SEC Accession No. 0001641172-25-004995
Filing Date
2025-04-16
Accepted
2025-04-16 13:35:50
Documents
16
Period of Report
2025-04-15
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41350
2 ex16-1.htm EX-16.1 1056
3 ex16-1_001.jpg GRAPHIC 136187
  Complete submission text file 0001641172-25-004995.txt   400201

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE pvct-20250415.xsd EX-101.SCH 3027
5 XBRL LABEL FILE pvct-20250415_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE pvct-20250415_pre.xml EX-101.PRE 22367
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3363
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36457 | Film No.: 25842030
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)